DrugPatentWatch Database Preview
NURTEC ODT Drug Profile
» See Plans and Pricing
Which patents cover Nurtec Odt, and what generic alternatives are available?
Nurtec Odt is a drug marketed by Biohaven Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has eighty-three patent family members in thirty-three countries.
The generic ingredient in NURTEC ODT is rimegepant sulfate. Additional details are available on the rimegepant sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Nurtec Odt
Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NURTEC ODT
| International Patents: | 83 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 27 |
| Clinical Trials: | 1 |
| Patent Applications: | 28 |
| Drug Prices: | Drug price information for NURTEC ODT |
| What excipients (inactive ingredients) are in NURTEC ODT? | NURTEC ODT excipients list |
| DailyMed Link: | NURTEC ODT at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NURTEC ODT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Weill Medical College of Cornell University | Phase 2 |
| Biohaven Pharmaceuticals, Inc. | Phase 2 |
US Patents and Regulatory Information for NURTEC ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biohaven Pharm | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Biohaven Pharm | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Biohaven Pharm | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NURTEC ODT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017226693 | Start Trial |
| Japan | 2015511581 | Start Trial |
| Australia | 2013226361 | Start Trial |
| Croatia | P20140111 | Start Trial |
| Eurasian Patent Organization | 020409 | Start Trial |
| South Korea | 20200016993 | Start Trial |
| Lithuania | 2820016 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
